TRANSFORMING GROWTH FACTOR-B EXPRESSION IN MELANOMA DEVELOPMENT AND PROGRESSION

黑色素瘤发展和进展中生长因子 B 表达的转化

基本信息

  • 批准号:
    6269086
  • 负责人:
  • 金额:
    $ 14.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-01-01 至 1999-06-30
  • 项目状态:
    已结题

项目摘要

The goal of this application is to define the role of tumor-associated transforming growth factor (TGF)-beta in the development of malignant melanoma. Previous work by this group demonstrated that TGF-beta is constitutively and persistently expressed by primary and malignant melanomas in vitro and in situ although TGF-beta inhibits melanoma growth in vitro. Based on these observations it is hypothesized that TGF-beta exerts effects in vivo that are essential to melanoma development and, thus, outweigh the growth-inhibitory effects observed in vitro. Relevant effects of TGF-beta include altered expression of adhesion molecules and proteolytic enzymes by melanoma cells, recruitment of host cells for local tumor growth and metastatic spread, and suppression of immune responses to tumor cells. Indirect evidence from other tumor systems suggests significant contributions of TGF-beta to all of these phenomena. The proposed experiments represent a direct approach to determine which of these potential effects of melanoma-derived TGF-beta are essential to melanoma development. Melanoma cell lines derived from distinct stages of progression and with defined tumorigenicity, metastatic capacity, immunogenicity, and TGF-beta effects is achieved by upregulation or suppression of TGF-beta production using sense, antisense, and negative dominant expression vectors in selected cell lines followed by in depth analysis of tumor growth and metastatic behavior. Effects on tumorigenicity in nude mice are studied by overexpressing TGF-beta in the non-tumorigenic human primary melanoma cell WM 1650. Effects on metastatic behavior are analyzed by suppressing TGF- beta production in the highly metastatic human 1205-LU cells. Effects on immunogenicity are examined by downmodulation of TGF-beta production in non-immunogenic mouse K1735 melanoma cell variants and the subsequent determination of immunogenicity in syngeneic, immunocompetent mice. In vitro studies will focus on TGF-beta dependent effects on adhesion, migration, and modulation of adhesion molecules and proteolytic enzymes in melanoma cells; immunological studies will focus on the effects of TGF-beta on different lymphocyte subsets. The long-term goal of these studies is to determine whether melanoma- derived TGF-beta provides a suitable therapeutic target.
本应用程序的目的是定义肿瘤相关的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ULRICH RODECK其他文献

ULRICH RODECK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ULRICH RODECK', 18)}}的其他基金

Monoclonal Antibody-based Prodrugs - Novel Tools for Cancer Therapy
基于单克隆抗体的前药 - 癌症治疗的新工具
  • 批准号:
    8013862
  • 财政年份:
    2010
  • 资助金额:
    $ 14.65万
  • 项目类别:
Monoclonal Antibody-based Prodrugs - Novel Tools for Cancer Therapy
基于单克隆抗体的前药 - 癌症治疗的新工具
  • 批准号:
    7788327
  • 财政年份:
    2010
  • 资助金额:
    $ 14.65万
  • 项目类别:
REGULATION OF KERATINOCYTE SURVIVAL
角质细胞存活的调节
  • 批准号:
    6478028
  • 财政年份:
    2001
  • 资助金额:
    $ 14.65万
  • 项目类别:
REGULATION OF KERATINOCYTE SURVIVAL
角质细胞存活的调节
  • 批准号:
    6173877
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
TRANSFORMING GROWTH FACTOR-B EXPRESSION IN MELANOMA DEVELOPMENT AND PROGRESSION
黑色素瘤发展和进展中生长因子 B 表达的转化
  • 批准号:
    6295884
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
REGULATION OF KERATINOCYTE SURVIVAL
角质细胞存活的调节
  • 批准号:
    2896780
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
Regulation of Keratinocyte Survival and Death
角质形成细胞存活和死亡的调节
  • 批准号:
    6866721
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
Regulation of Keratinocyte Survival and Death
角质形成细胞存活和死亡的调节
  • 批准号:
    6704216
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
Regulation of Keratinocyte Survival and Death
角质形成细胞存活和死亡的调节
  • 批准号:
    7025817
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:
Regulation of Keratinocyte Survival and Death
角质形成细胞存活和死亡的调节
  • 批准号:
    6625666
  • 财政年份:
    1998
  • 资助金额:
    $ 14.65万
  • 项目类别:

相似海外基金

REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056554
  • 财政年份:
    1990
  • 资助金额:
    $ 14.65万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056556
  • 财政年份:
    1989
  • 资助金额:
    $ 14.65万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056555
  • 财政年份:
    1988
  • 资助金额:
    $ 14.65万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056553
  • 财政年份:
    1987
  • 资助金额:
    $ 14.65万
  • 项目类别:
The Athymic Mouse As a Model For the Study of Keloids
无胸腺小鼠作为瘢痕疙瘩研究的模型
  • 批准号:
    7816691
  • 财政年份:
    1978
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了